Literature DB >> 9813136

Inhibition of alanyl aminopeptidase induces MAP-kinase p42/ERK2 in the human T cell line KARPAS-299.

U Lendeckel1, T Kähne, M Arndt, K Frank, S Ansorge.   

Abstract

Inhibition of alanyl aminopeptidase (EC 3.4.11.2, aminopeptidase N, CD13) expression, or activity compromise cell proliferation in a number of cell systems [1, 2, 3, 4, 5, 6]. The underlying mechanisms and the molecular components involved have not been identified as yet. In this study we show that inhibition of alanyl aminopeptidase enzymatic activity decreases the proliferation rate of the CD13-positive T cell line Karpas-299. By using the ATLAS cDNA expression array (Clontech) we identified the p42/ERK2 MAP kinase as one downstream target of probestin, a potent inhibitor of alanyl aminopeptidase. Probestin and another specific aminopeptidase inhibitor, actinonin, in addition to their capability of inducing erk-2 mRNA levels, significantly increase p42 phosphorylation state. This is the first report on signal transduction components possibly mediating the growth-modulatory effects of alanyl aminopeptidase inhibitors. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9813136     DOI: 10.1006/bbrc.1998.9585

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  A profiling platform for the identification of selective metalloprotease inhibitors.

Authors:  Christophe Antczak; Constantin Radu; Hakim Djaballah
Journal:  J Biomol Screen       Date:  2008-03-18

Review 2.  CD13/Aminopeptidase N Is a Potential Therapeutic Target for Inflammatory Disorders.

Authors:  Chenyang Lu; Mohammad A Amin; David A Fox
Journal:  J Immunol       Date:  2020-01-01       Impact factor: 5.422

3.  CD13 is dispensable for normal hematopoiesis and myeloid cell functions in the mouse.

Authors:  Beata Winnicka; Catherine O'Conor; Wolfgang Schacke; Kaitlyn Vernier; Christina L Grant; Fiona Hall Fenteany; Flavia E Pereira; Brannen Liang; Anupinder Kaur; Ran Zhao; David C Montrose; Daniel W Rosenberg; Hector L Aguila; Linda H Shapiro
Journal:  J Leukoc Biol       Date:  2010-04-29       Impact factor: 4.962

4.  Aminopeptidase N1 (EtAPN1), an M1 metalloprotease of the apicomplexan parasite Eimeria tenella, participates in parasite development.

Authors:  Simon Gras; Anna Byzia; Florence B Gilbert; Sheena McGowan; Marcin Drag; Anne Silvestre; Alisson Niepceron; Fabien Lecaille; Gilles Lalmanach; Fabien Brossier
Journal:  Eukaryot Cell       Date:  2014-05-16

5.  Quaternary benzo[c]phenanthridine alkaloids as inhibitors of aminopeptidase N and dipeptidyl peptidase IV.

Authors:  Aleksi Sedo; Kvetoslava Vlasicová; Petr Barták; Radim Vespalec; Jaroslav Vicar; Vilim Simánek; Jitka Ulrichová
Journal:  Phytother Res       Date:  2002-02       Impact factor: 5.878

Review 6.  Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects.

Authors:  Brigitte Bauvois; Daniel Dauzonne
Journal:  Med Res Rev       Date:  2006-01       Impact factor: 12.944

Review 7.  Opioids, Neutral Endopeptidase, its Inhibitors and Cancer: Is There a Relationship among them?

Authors:  Magdalena Mizerska-Dudka; Martyna Kandefer-Szerszeń
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2014-09-06       Impact factor: 4.291

8.  Mesenchymal Stem Cells From Infants Born to Obese Mothers Exhibit Greater Potential for Adipogenesis: The Healthy Start BabyBUMP Project.

Authors:  Kristen E Boyle; Zachary W Patinkin; Allison L B Shapiro; Peter R Baker; Dana Dabelea; Jacob E Friedman
Journal:  Diabetes       Date:  2015-12-02       Impact factor: 9.461

9.  Inhibitory effect of antisense aminopeptidase N (APN/CD13) cDNA transfection on the invasive potential of osteosarcoma cells.

Authors:  Akira Kido; Sabine Krueger; Carsten Haeckel; Albert Roessner
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.